Kyntra Bio files 8-K covering a debt obligation

Kyntra Bio, Inc., a pharmaceutical preparations company listed on Nasdaq under the ticker KYNB, filed an 8-K on 2026-08-31.^[1][2]

The filing carries a debt obligation event, was filed on 2026-08-31, and covers the period ending 2026-08-31.^[1]

The 8-K, filed under accession number 0001193125-26-377059, includes items 1.01, 2.03, 7.01, and 9.01.^[1]

The matched document for the filing is kynb-20260831.htm.^[1]

Separately, the company received a delisting notice dated 2026-04-09.^[3]